Shares of AxoGen (NASDAQ: AXGN), a leading medical technology company focused on peripheral nerve repair, plummeted by 7.96% on November 7, 2024, despite the company reporting solid third-quarter results and maintaining its full-year guidance.
AxoGen's third-quarter revenue grew by 17.9% year-over-year to $48.6 million, exceeding analysts' expectations of $47.07 million. The company attributed the robust revenue growth to improved sales productivity and commercial execution across its entire portfolio of nerve repair and protection applications.
Notably, AxoGen reported an adjusted net income of $3.1 million, or $0.07 per share, significantly higher than the adjusted net loss of $0.7 million, or $0.01 per share, in the same period last year. This also surpassed analysts' estimates of $0.01 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.